Skip to Main Content

Paper Details

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Nature
331
2022
(CAR) T cells, CAR, CAR T cell, CAR T cell products, DIPG, DMGs, Diffuse intrinsic pontine glioma, GD2, GD2-CAR T cell, GD2-CAR T cells, H3K27M, H3K27M-mutated glioma cells, Patients, brainstem inflammation, diffuse midline gliomas, disialoganglioside GD2, human, obstructive hydrocephalus, paediatric tumours of the central nervous system, participants, patients, plasma, single cells, spinal cord DMG, tumour
Author NameAffiliation
Katherine E WarrenDana Farber Cancer Institute
Lindsey RasmussenStanford University
Timothy T CornellStanford University
Sonia PartapStanford University
Sonia PartapStanford University
Paul G FisherStanford University
Mariella G FilbinDana Farber Cancer Institute
Kara L DavisStanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University
Kara L DavisStanford University
Kara L DavisStanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University
Kara L DavisStanford University
Michelle MonjeStanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University
Michelle MonjeStanford University
Michelle MonjeStanford University
Michelle MonjeStanford University
Michelle MonjeStanford University
Michelle MonjeHoward Hughes Medical Institute, Stanford University
  • 1 - 17

Datasets

Release 1.2